Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Eli Lilly Stock Slumped Today


A price war for weight-loss drugs is intensifying, and it's clear Eli Lilly (NYSE: LLY) investors weren't happy about it. On news that the company's arch-rival in the category had cut prices for several of its medications, those folks sold out of Eli Lilly stock to push it to a nearly 2% loss on Tuesday.

That rival is Danish pharmaceutical company Novo Nordisk, best-known for its Wegovy obesity treatment that directly competes with Eli Lilly's Zepbound. Early Tuesday morning, Novo Nordisk announced a set of price cuts to its leading products, including Wegovy.

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
LLY
Share

Comments